| HOME >> MEDICINE >> TECHNOLOGY |
Advertisements 52
FDA Launches 'Bad Ad Program', Industry Vents Concerns 52
FDA in Action Mode Amid Wide Concerns; Number of FDA Warning
Letters Rise 52
Warning Letters Issued by DDMAC in 2011 53
Warning Letters Issued by DDMAC in 2010 54
Warning Letters Issued by DDMAC in 2009 55
9. DTC ADVERTISING IN SELECT OTHER COUNTRIES 58
New Zealand 58
DTC Advertising Regulations in New Zealand - An Overview 58
Industry Self Regulation on DTC - A Major Driver 58
DTC Regulation in the New Zealand Versus the US 59
A Brief Comparison of Regulatory Requirements on Content in
DTC Advertising in the US and New Zealand 59
The Road Ahead for DTC Advertising in New Zealand 59
Australia 60
Earlier Reviews Fail to Approve DTC Advertising in the Country 60
The Therapeutic Products Authority 60
Canada 61
Canadian Pharmaceutical Ad Spending - A Historic Perspective 61
Table 9: Leading Canadian Pharmaceutical Brands by
Advertising Spending: 2001-2006 (includes corresponding
Graph/Chart) 61
Table 10: DTC Pharmaceutical Ad Spending in Canada by Media
Channel (2004-2006): Spending in US$ Million for TV & Radio,
Print Media, and Outdoor Media (includes corresponding
Graph/Chart) 62
Policy Revisions Pave Way for Partiasl Relaxation of DTC Laws 62
The Unique Stature of Canadian Policy on DTC Advertising 62
Europe 63
The Present State of Pharmaceutical DTC Advertising in Europe 63
Several Efforts to Allow DTC Advertising in Europe Go in Vain 63
Of late Some Headway Emerges 64
Latest Proposal to Approve Limited DTC Offers Some Hope 65
New Avenues for Communication to Shape Future of DTC 65
10. DTC ADVERTISING - A BRIEF OVERVIEW 66
An Introduction to Direct-To-Consumer Advertising 66
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |